Seattle Genetics, Inc. (SGEN) Reaches $54.19 After 8.00% Up Move, Macquarie Group LTD Raised Incyte (INCY) Holding

June 28, 2017 - By Clifton Ray

Macquarie Group Ltd increased Incyte Corp (INCY) stake by 156.59% reported in 2016Q4 SEC filing. Macquarie Group Ltd acquired 65,344 shares as Incyte Corp (INCY)’s stock rose 9.08%. The Macquarie Group Ltd holds 107,073 shares with $10.74 million value, up from 41,729 last quarter. Incyte Corp now has $26.54B valuation. The stock rose 2.77% or $3.61 reaching $133.92 per share. About 629,307 shares traded. Incyte Corporation (NASDAQ:INCY) has risen 72.84% since June 28, 2016 and is uptrending. It has outperformed by 56.14% the S&P500.

The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) is a huge mover today! About 1.73 million shares traded or 39.52% up from the average. Seattle Genetics, Inc. (NASDAQ:SGEN) has risen 75.68% since June 28, 2016 and is uptrending. It has outperformed by 58.98% the S&P500.The move comes after 7 months positive chart setup for the $7.03 billion company. It was reported on Jun, 28 by Barchart.com. We have $58.53 PT which if reached, will make NASDAQ:SGEN worth $562.40 million more.

Among 10 analysts covering Seattle Genetics (NASDAQ:SGEN), 3 have Buy rating, 1 Sell and 6 Hold. Therefore 30% are positive. Seattle Genetics has $72 highest and $51 lowest target. $60.33’s average target is 11.33% above currents $54.19 stock price. Seattle Genetics had 20 analyst reports since July 31, 2015 according to SRatingsIntel. The rating was initiated by Barclays Capital on Thursday, February 4 with “Overweight”. The firm has “Outperform” rating given on Monday, September 14 by RBC Capital Markets. As per Friday, October 30, the company rating was upgraded by Piper Jaffray. Credit Suisse initiated the shares of SGEN in report on Thursday, January 21 with “Outperform” rating. The firm has “Equal-Weight” rating given on Tuesday, November 29 by Barclays Capital. RBC Capital Markets maintained the stock with “Outperform” rating in Friday, July 31 report. Barclays Capital maintained it with “Overweight” rating and $53 target in Wednesday, July 27 report. The firm has “Hold” rating by Oppenheimer given on Friday, June 2. The rating was maintained by William Blair with “Buy” on Tuesday, August 25. The firm has “Outperform” rating by RBC Capital Markets given on Tuesday, December 6.

Since January 6, 2017, it had 0 insider purchases, and 8 sales for $6.45 million activity. SIEGALL CLAY B sold $679,698 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) on Monday, June 5. On Friday, March 31 HIMES VAUGHN B sold $627,527 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) or 10,000 shares.

Analysts await Seattle Genetics, Inc. (NASDAQ:SGEN) to report earnings on July, 25. They expect $-0.44 earnings per share, down 91.30% or $0.21 from last year’s $-0.23 per share. After $-0.42 actual earnings per share reported by Seattle Genetics, Inc. for the previous quarter, Wall Street now forecasts 4.76% negative EPS growth.

Investors sentiment increased to 1.2 in Q4 2016. Its up 0.20, from 1 in 2016Q3. It is positive, as 30 investors sold Seattle Genetics, Inc. shares while 73 reduced holdings. 60 funds opened positions while 64 raised stakes. 135.77 million shares or 1.02% less from 137.16 million shares in 2016Q3 were reported. Moreover, Morgan Stanley has 0% invested in Seattle Genetics, Inc. (NASDAQ:SGEN). Financial Bank Of Montreal Can reported 0% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN). Moreover, Laurion Mngmt L P has 0% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 5,250 shares. Carl Domino reported 0.3% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN). D E Shaw Inc reported 0.01% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN). Manufacturers Life Communications The stated it has 4,555 shares. Moreover, Creative Planning has 0.02% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 49,770 shares. Nomura Asset Mgmt Communications Limited holds 0.01% in Seattle Genetics, Inc. (NASDAQ:SGEN) or 10,800 shares. Barclays Public Ltd Co has 41,215 shares for 0% of their portfolio. Primecap Mngmt Ca invested in 13.23 million shares or 0.69% of the stock. 67,254 were reported by Sg Americas Securities Ltd Liability Corp. Cornerstone invested in 0.01% or 150 shares. 88,350 are held by Dekabank Deutsche Girozentrale. Grandfield & Dodd Ltd Liability Corporation has 0.06% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 9,411 shares. Daiwa Gp holds 0% or 400 shares in its portfolio.

Seattle Genetics, Inc. is a biotechnology firm focused on the development and commercialization of therapies for the treatment of cancer. The company has market cap of $7.03 billion. The Firm is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. It currently has negative earnings. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate .

Among 19 analysts covering Incyte (NASDAQ:INCY), 16 have Buy rating, 0 Sell and 3 Hold. Therefore 84% are positive. Incyte had 44 analyst reports since August 6, 2015 according to SRatingsIntel. BMO Capital Markets initiated the shares of INCY in report on Thursday, April 7 with “Outperform” rating. The firm earned “Outperform” rating on Monday, January 23 by Credit Suisse. The firm earned “Buy” rating on Wednesday, August 12 by Zacks. The firm has “Overweight” rating by Barclays Capital given on Friday, February 12. On Friday, February 12 the stock rating was maintained by Oppenheimer with “Outperform”. Morgan Stanley initiated it with “Overweight” rating and $85 target in Wednesday, March 23 report. The rating was initiated by Credit Suisse on Wednesday, January 20 with “Outperform”. Brean Capital maintained the stock with “Buy” rating in Friday, February 12 report. The stock of Incyte Corporation (NASDAQ:INCY) has “Buy” rating given on Wednesday, August 5 by Brean Capital. The rating was initiated by RBC Capital Markets on Wednesday, July 13 with “Outperform”.

Investors sentiment increased to 1.23 in Q4 2016. Its up 0.08, from 1.15 in 2016Q3. It increased, as 32 investors sold INCY shares while 130 reduced holdings. 66 funds opened positions while 133 raised stakes. 173.11 million shares or 1.04% more from 171.33 million shares in 2016Q3 were reported. Reilly Fincl Advsr Llc holds 0.01% in Incyte Corporation (NASDAQ:INCY) or 295 shares. Cibc Ww Markets Corp reported 0.57% stake. Blackrock Japan Limited holds 221,138 shares. Federated Investors Pa has 577,141 shares. Vanguard Grp Inc holds 0.07% or 12.57 million shares. Lincoln National has invested 0.02% in Incyte Corporation (NASDAQ:INCY). Torray Llc owns 180,511 shares or 1.93% of their US portfolio. Commonwealth Equity Services holds 7,669 shares. 4,437 were accumulated by Allen Investment Mgmt Ltd Liability. Ww Asset Mgmt holds 6,025 shares. Oxford Asset invested in 10,592 shares or 0.05% of the stock. Teacher Retirement Sys Of Texas owns 4,768 shares. 609,490 are held by Canada Pension Plan Inv Board. Lazard Asset Mngmt Ltd Limited Liability Company has invested 0% in Incyte Corporation (NASDAQ:INCY). Sectoral Asset Mngmt has 34,374 shares for 0.38% of their portfolio.